Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma : importance of immunoglobulin supplementation
© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
ABSTRACT: Teclistamab and other B-cell maturation antigen (BCMA)-targeting bispecific antibodies (BsAbs) have substantial activity in patients with heavily pretreated multiple myeloma (MM) but are associated with a high rate of infections. BCMA is also expressed on normal plasma cells and mature B cells, which are essential for the generation of a humoral immune response. The aim of this study was to improve the understanding of the impact of BCMA-targeting BsAbs on humoral immunity. The impact of teclistamab on polyclonal immunoglobulins and B cell counts was evaluated in patients with MM who received once-weekly teclistamab 1.5 mg/kg subcutaneously. Vaccination responses were assessed in a subset of patients. Teclistamabinduced rapid depletion of peripheral blood B cells in patients with MM and eliminated normal plasma cells in ex vivo assays. In addition, teclistamab reduced the levels of polyclonal immunoglobulins (immunoglobulin G [IgG], IgA, IgE, and IgM), without recovery over time while receiving teclistamab therapy. Furthermore, response to vaccines against Streptococcus pneumoniae, Haemophilus influenzae type B, and severe acute respiratory syndrome coronavirus 2 was severely impaired in patients treated with teclistamab compared with vaccination responses observed in patients with newly diagnosed MM or relapsed/refractory MM. Intravenous immunoglobulin (IVIG) use was associated with a significantly lower risk of serious infections among patients treated with teclistamab (cumulative incidence of infections at 6 months: 5.3% with IVIG vs 54.8% with observation only [P < .001]). In conclusion, our data show severe defects in humoral immunity induced by teclistamab, the impact of which can be mitigated by the use of immunoglobulin supplementation. This trial was registered at www.ClinicalTrials.gov as #NCT04557098.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Blood advances - 8(2024), 1 vom: 09. Jan., Seite 194-206 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Frerichs, Kristine A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Bispecific |
|---|
| Anmerkungen: |
Date Completed 01.01.2024 Date Revised 15.01.2024 published: Print ClinicalTrials.gov: NCT04557098 Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2023011658 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365429651 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365429651 | ||
| 003 | DE-627 | ||
| 005 | 20240115231936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2023011658 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1260.xml |
| 035 | |a (DE-627)NLM365429651 | ||
| 035 | |a (NLM)38052042 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Frerichs, Kristine A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma |b importance of immunoglobulin supplementation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.01.2024 | ||
| 500 | |a Date Revised 15.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT04557098 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a ABSTRACT: Teclistamab and other B-cell maturation antigen (BCMA)-targeting bispecific antibodies (BsAbs) have substantial activity in patients with heavily pretreated multiple myeloma (MM) but are associated with a high rate of infections. BCMA is also expressed on normal plasma cells and mature B cells, which are essential for the generation of a humoral immune response. The aim of this study was to improve the understanding of the impact of BCMA-targeting BsAbs on humoral immunity. The impact of teclistamab on polyclonal immunoglobulins and B cell counts was evaluated in patients with MM who received once-weekly teclistamab 1.5 mg/kg subcutaneously. Vaccination responses were assessed in a subset of patients. Teclistamabinduced rapid depletion of peripheral blood B cells in patients with MM and eliminated normal plasma cells in ex vivo assays. In addition, teclistamab reduced the levels of polyclonal immunoglobulins (immunoglobulin G [IgG], IgA, IgE, and IgM), without recovery over time while receiving teclistamab therapy. Furthermore, response to vaccines against Streptococcus pneumoniae, Haemophilus influenzae type B, and severe acute respiratory syndrome coronavirus 2 was severely impaired in patients treated with teclistamab compared with vaccination responses observed in patients with newly diagnosed MM or relapsed/refractory MM. Intravenous immunoglobulin (IVIG) use was associated with a significantly lower risk of serious infections among patients treated with teclistamab (cumulative incidence of infections at 6 months: 5.3% with IVIG vs 54.8% with observation only [P < .001]). In conclusion, our data show severe defects in humoral immunity induced by teclistamab, the impact of which can be mitigated by the use of immunoglobulin supplementation. This trial was registered at www.ClinicalTrials.gov as #NCT04557098 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 650 | 7 | |a Antibodies, Bispecific |2 NLM | |
| 650 | 7 | |a B-Cell Maturation Antigen |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Verkleij, Christie P M |e verfasserin |4 aut | |
| 700 | 1 | |a Mateos, Maria Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Thomas G |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez, Cesar |e verfasserin |4 aut | |
| 700 | 1 | |a Nooka, Ajay |e verfasserin |4 aut | |
| 700 | 1 | |a Banerjee, Arnob |e verfasserin |4 aut | |
| 700 | 1 | |a Chastain, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Perales-Puchalt, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Stephenson, Tara |e verfasserin |4 aut | |
| 700 | 1 | |a Uhlar, Clarissa |e verfasserin |4 aut | |
| 700 | 1 | |a Kobos, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a van der Holt, Bronno |e verfasserin |4 aut | |
| 700 | 1 | |a Kruyswijk, Sandy |e verfasserin |4 aut | |
| 700 | 1 | |a Kuipers, Maria T |e verfasserin |4 aut | |
| 700 | 1 | |a Groen, Kaz |e verfasserin |4 aut | |
| 700 | 1 | |a Vishwamitra, Deeksha |e verfasserin |4 aut | |
| 700 | 1 | |a Skerget, Sheri |e verfasserin |4 aut | |
| 700 | 1 | |a Cortes-Selva, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Doyle, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Zaaijer, Hans L |e verfasserin |4 aut | |
| 700 | 1 | |a Zweegman, Sonja |e verfasserin |4 aut | |
| 700 | 1 | |a Verona, Raluca I |e verfasserin |4 aut | |
| 700 | 1 | |a van de Donk, Niels W C J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 8(2024), 1 vom: 09. Jan., Seite 194-206 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:1 |g day:09 |g month:01 |g pages:194-206 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2023011658 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 1 |b 09 |c 01 |h 194-206 | ||